US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib

Bookmark and Share
Published: 13 Jun 2020
Views: 289
Rating:
Save
Dr Sudhir Manda - Arizona Oncology / US Oncology Research, Tucson, USA

Dr Sudhir Manda speaks to ecancer about the study he presented during the EHA 2020 virtual meeting.

He presents the US MM-6 study, a community-based study looking at long-term proteasome inhibition in multiple myeloma (MM) following an in-class transition from bortezomib (btz) to ixazomib (ixa).

Dr Manda gives a detailed account of the trial design, results and the ongoing enrolment status of this clinical trial. He finalises by explaining what clinical and patient impact this research will have.